A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2-Metastatic Breast Cancer.

Palbociclib in molecularly characterized ER-positive/HER2-negative metastatic breast cancer: the PYTHIA study.

Study Chair
Dr. Luca Malorni (Prato, Italy)

Statistician
Meredith Regan, ScD

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Poonam Jani

Data Manager
Adriana Mora de Karausch, Monica Greco

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Trial Monitors
Daniela Celotto, Carmen Comune

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
August 28, 2015

Targeted Accrual
122

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login